Silence Therapeutics (SLN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kostas Biliouris from BMO Capital maintained a Buy rating on the stock and has a $15.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kostas Biliouris has given his Buy rating due to a combination of factors related to Silence Therapeutics’ promising developments. The final Phase I data for Divesiran highlights its strong efficacy and safety profile in treating polycythemia vera (PV), with the potential for less frequent dosing. This positions Divesiran as a potential best-in-class treatment, which could significantly enhance Silence Therapeutics’ market position as the Phase II data readout approaches in the second half of 2026.
Biliouris also notes the commercial potential of Silence Therapeutics’ Zerlasiran program, which has shown impressive results in lowering lipoprotein(a) levels. The clean safety profile and low dosing frequency of Zerlasiran could attract partnership interest, providing additional upside for the company. Furthermore, the high unmet need in the PV market, evidenced by significant sales of existing treatments despite their limitations, underscores the opportunity for Silence Therapeutics to capture a substantial market share with its innovative therapies.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $75.00 price target.